To evaluate the effect of idalopirdine (120 and 360 mg) on cardiac repolarisation in healthy men.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
76
Capsules, orally, single dose
Two 60 mg encapsulated film-coated tablets, orally, single dose
Four 90 mg encapsulated film-coated tablets, orally, single dose
FR801
Rennes, France
Change from pre-dose baseline in the QT interval (ΔQTcF) at each post-dose time point within the ECG collection period
The QT interval will be corrected for heart rate by using the Fridericia's method (QTcF)
Time frame: For 24 hours in each dosing period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Encapsulated tablets, orally, single dose